Kihealth, a leader in molecular diagnostics, today announced it has won the Innovation of the Year challenge at the American Diabetes Association’s 85th Scientific Session held in Chicago. Kihealth’s pioneering liquid-biopsy test, which measures the rate of pancreatic beta‑cell death, earned top honors among five finalists for its potential to revolutionize early diabetes detection.
Dubbed the “Super Bowl of diabetes innovation,” this prestigious award has firmly established Kihealth and its products in the spotlight. The honor follows a live pitch to a panel of expert judges and a global audience of clinicians, researchers, and industry leaders. In winning first place, Kihealth stood out for delivering a novel diagnostic that provides patients and clinicians with a critical early window into metabolic health – years before glucose or A1c abnormalities appear prnewswire.com.
Key Highlights & Immediate Impact
- Surge in physician engagement: Following the win, Kihealth has received new contracts and strong interest from healthcare providers nationwide.
- Increased funding & partnerships: The recognition triggered follow-up discussions with institutional payers and wellness platforms exploring early-risk screening.
- Product visibility & credibility: The award signals clear validation of Kihealth’s molecular assay and commitment to elevating standards of preventive care.
“This is a monumental milestone,” said Jennifer Anderson, CEO of Kihealth. “Winning ADA’s Innovation of the Year at the 85th Scientific Sessions is the ultimate validation of our mission to enable earlier, more actionable insights into disease risk. It’s sparked tremendous momentum—from physician interest and contract discussions to expanded visibility. We’re just getting started.”
Discover the latest trends and insights—explore the Business Insights Journal for up-to-date strategies and industry breakthroughs!
